Core Viewpoint - The Navan class action lawsuit alleges that Navan, Inc. and its executives misled investors regarding the company's financial health during its IPO, leading to significant stock price declines after the announcement of increased expenses [1][3][4]. Group 1: Class Action Lawsuit Details - The lawsuit, titled McCown v. Navan, Inc., allows purchasers of Navan's common stock from its October 31, 2025 IPO to seek lead plaintiff status by April 24, 2026 [1][2]. - Navan's IPO involved the issuance of nearly 37 million shares at an offering price of $25.00 per share [2]. - The lawsuit claims that the offering documents were materially false or misleading, particularly regarding a 39% increase in sales and marketing expenses shortly after the IPO [3]. Group 2: Financial Impact and Stock Performance - On December 15, 2025, Navan reported a 39% increase in sales and marketing expenses, rising to nearly $95 million from $68.5 million in the previous quarter [4]. - Following this announcement, Navan's stock price fell nearly 12% [4]. - By the time the lawsuit commenced, Navan's stock had traded as low as $9.20 per share, representing a decline of nearly 63% from the IPO price [5]. Group 3: Legal Process and Firm Background - The Private Securities Litigation Reform Act of 1995 allows investors who purchased Navan stock during the IPO to seek lead plaintiff status, which enables them to represent the interests of the class [6]. - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized as a leading firm in securities fraud litigation, having recovered over $916 million for investors in 2025 alone [7].

Core Viewpoint - Aardvark Therapeutics, Inc. is under investigation for potential securities fraud and unlawful business practices following a significant stock price drop due to the voluntary pause of its Phase 3 HERO trial [1][3]. Group 1: Company Actions - On February 27, 2026, Aardvark announced the voluntary pause of the Phase 3 Hunger Elimination or Reduction Objective (HERO) trial due to reversible cardiac observations at above target therapeutic doses found during routine safety monitoring [3]. - The company is conducting a comprehensive review of the data to inform next steps regarding the HERO trial [3]. Group 2: Market Reaction - Following the announcement of the trial pause, Aardvark's stock price fell by $7.02 per share, representing a 56.2% decrease, closing at $5.47 per share on March 2, 2026 [3]. Group 3: Legal Investigation - Pomerantz LLP is investigating claims on behalf of Aardvark investors regarding potential securities fraud or other unlawful business practices by the company and its officers and/or directors [1].

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Apollo Global Management, Inc. (“Apollo” or the “Company”) (NYSE: APO).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.  The class action concerns whether Apollo and certa ...

Core Viewpoint - The PayPal class action lawsuit alleges that the company and certain executives misled investors regarding the company's revenue outlook and growth potential during the Class Period, leading to significant financial losses for shareholders [3][4]. Group 1: Lawsuit Details - The class action lawsuit is titled Goodman v. PayPal Holdings, Inc., and it involves purchasers of PayPal common stock from February 25, 2025, to February 2, 2026 [1]. - Investors have until April 20, 2026, to seek appointment as lead plaintiff in the lawsuit [1]. - The lawsuit claims that PayPal's executives created a false impression of the company's financial health and growth prospects, which were not achievable under the leadership of CEO James Alexander Chriss [3]. Group 2: Financial Performance - On February 3, 2026, PayPal announced disappointing financial results for Q4 and the full fiscal year 2025, including a decline in performance in Branded Checkout and the withdrawal of previously set 2027 financial targets [4]. - The company attributed its poor performance to macroeconomic factors, competition, and operational issues, which led to a more than 20% drop in PayPal's stock price following the announcement [4]. Group 3: Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased PayPal stock during the Class Period to seek lead plaintiff status, representing the interests of the class [5]. - The lead plaintiff can choose a law firm to litigate the case, and participation as lead plaintiff does not affect an investor's ability to share in any potential recovery [5]. Group 4: Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [6]. - The firm has a strong track record, recovering $8.4 billion for investors over the past five years, making it one of the largest plaintiffs' firms globally [6].

Core Viewpoint - A class action lawsuit has been filed against Franklin BSP Realty Trust, Inc. for alleged securities fraud and unlawful business practices [2]. Group 1: Lawsuit Details - The lawsuit involves Franklin and certain officers and/or directors accused of engaging in securities fraud or other unlawful business practices [2]. - Investors have until April 27, 2026, to request appointment as Lead Plaintiff if they purchased Franklin securities during the Class Period [2]. Group 2: Recent Company Developments - On February 10, 2026, Franklin appointed a new Chief Executive Officer and President, which led to a stock price decline of $0.10 per share, or 0.98%, closing at $10.25 on February 11, 2026 [4]. - Franklin reported fourth quarter earnings per share of $0.12, missing consensus estimates by $0.16, and revenue of $81.12 million, compared to the consensus estimate of $93.65 million [5]. - Following the financial results announcement, Franklin's stock price fell by $1.44 per share, or 14.19%, closing at $8.71 on February 12, 2026 [5].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Camping World Holdings, Inc. and its officers or directors [1] Financial Performance - On October 29, 2025, Camping World reported a reduction in 2026 EBITDA guidance to $310 million, attributed to inventory management issues, leading to a stock price drop of $4.17 per share (24.8%) to close at $12.65 [3] - On February 25, 2026, the company announced a net loss of $(109.1) million, an increase of 83.3%, and a total gross margin of 28.8%, down 247 basis points, resulting in a further stock price decline of $1.79 per share (16.5%) to close at $9.06 [4] Company Actions - CEO Marcus Lemonis emphasized the need for the team to liquidate inventory to address financial challenges [3] - The company implemented strict inventory management objectives to improve turnover rates, which are expected to create gross margin headwinds in the first half of 2026 [4]

Core Viewpoint - Ziff Davis, Inc. is under investigation for potential violations of federal securities laws, which may indicate underlying issues in its financial reporting and performance metrics [1]. Financial Performance - In 2025, Ziff Davis emphasized adjusted EBITDA and adjusted diluted EPS as key performance indicators, with the Q2 2025 adjusted diluted EPS reported at $1.24, attributed to higher adjusted EBITDA and a reduction in diluted shares outstanding [2]. - The Q4 2025 results showed a revenue decline of 1.5% year-over-year to $406.7 million, and the adjusted EPS fell short of both consensus and internal projections, leading to a significant drop in stock price [3].

New York, New York--(Newsfile Corp. - March 3, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into PROCEPT BioRobotics Corporation ("PROCEPT BioRobotics Corporation") (NASDAQ: PRCT) concerning potential violations of the federal securities laws.On the Q3 2025 earnings call on November 4, 2025, CFO Kevin Waters reaffirmed the $325.5 million revenue target and stated the company was "maintaining handpiece average selling prices to be approximately $3,200." CEO Larry Wood a ...

Core Viewpoint - Gossamer Bio, Inc. is under investigation by Levi & Korsinsky for potential violations of federal securities laws, particularly related to the results of its pivotal Phase 3 trial for the drug Seralutinib [1]. Group 1: Company Overview - Gossamer Bio's lead pipeline candidate is Seralutinib, which was evaluated in the PROSERA study for pulmonary arterial hypertension [2]. - The PROSERA trial aimed to demonstrate a treatment effect in a patient population that the company believed was well-suited for the study [2]. Group 2: Trial Results - During the Q1 2025 earnings call, CEO Faheem Hasnain expressed optimism about the trial results, stating that the baseline characteristics were targeted and that the company had "over 90% power given the sample size" [3]. - Despite reaching the planned enrollment target, the primary efficacy endpoint of the trial did not achieve the prespecified level of statistical significance [3].

Core Viewpoint - Driven Brands Holdings Inc. is under investigation for potential violations of federal securities laws, following a significant drop in share price after announcing a delay in earnings release and restatement of prior fiscal results [1][2]. Financial Guidance Summary - Throughout FY 2025, Driven Brands provided specific financial guidance during quarterly earnings calls, with the following key figures: - Q4 2024 guidance: Revenue of $2.05 billion to $2.15 billion, adjusted EBITDA of $520 million to $550 million, adjusted diluted EPS of $1.15 to $1.25 [2]. - Q1 and Q2 2025 calls reiterated the same outlook ranges [2]. - Q3 2025 call narrowed guidance to revenue of $2.1 billion to $2.12 billion, adjusted EBITDA of $525 million to $535 million, and adjusted EPS of $1.23 to $1.28, citing strong third-quarter performance [2]. - On February 25, 2026, the company announced a delay in the FY 2025 results and disclosed that prior fiscal results would be restated, leading to a 40% drop in DRVN shares [2].